Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD20 Dual-Target in vivo CAR-T Lentiviral in Relapsed/Refractory B-cell Malignancies
NCT07002112Phase 1Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2025
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LVIVO-TaVec100 in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Treatment-emergent Adverse Events at 2 years, Pharmacokinetics in peripheral blood at 2 years and 2 more. Started May 2025; status: recruiting.
02
Drugs
LVIVO-TaVec100
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT07002112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07002112.